Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the use of 5α-reductase inhibitors, particularly finasteride, for treating conditions like benign prostatic hyperplasia, male baldness, and hirsutism, and reports no new clinical results.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.

This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.

This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

This study found that oral administration of finasteride to pregnant rats caused dosage-related developmental toxicities, including hypospadias and decreased anogenital distance in male offspring.

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.

This research article focuses on nonsteroidal inhibitors of human type I steroid 5-alpha-reductase but reports no new results.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

This study found that both finasteride and flutamide effectively reduce hirsutism in women with polycystic ovary syndrome or idiopathic hirsutism, but flutamide was more effective.

This study found that oral finasteride was more effective than 5% topical minoxidil in treating mild to severe androgenetic alopecia in males, with both treatments deemed effective and safe over 12 months.

In this study, women with idiopathic hirsutism who took finasteride for 9 months experienced a significant reduction in hirsutism scores compared to those receiving a placebo, with minimal side effects.

This study reported new crystallographic structures and polymorphs of finasteride, including several solvates with distinct X-ray diffraction patterns and thermally characterized properties.

This study found that 4 weeks of finasteride treatment significantly decreased DHT levels in bald scalp to levels similar to hair-containing scalp in men with male pattern baldness.

Finasteride reduces hair loss and treats BPH without major hormone changes, but may cause sexual dysfunction.

This study found that a combination therapy of Diane 35 with finasteride was more effective at reducing hirsutism scores in women with idiopathic hirsutism or polycystic ovary syndrome after 3 months compared to Diane 35 alone.

This study found that women with androgenetic alopecia showed higher levels of certain hormones and lower levels of sex hormone-binding globulin than healthy controls, potentially linking these factors to alopecia severity.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

This study found that topical finasteride and flutamide both significantly reduced sebaceous gland growth and decreased prostatic weights in hamsters, indicating systemic effects despite local application.

This study found that St. John's wort treatment for two weeks induced finasteride metabolism and reduced its plasma exposure in healthy men.

This review examines the pharmacology, clinical efficacy, and adverse effects of oral finasteride for female pattern hair loss, and discusses potential new treatments like topical finasteride and dutasteride, but reports no new clinical results.

This review discusses the use of antiandrogen therapy in dermatology, covering treatments for conditions like acne, hirsutism, and androgenic alopecia but reports no new clinical findings.

This article reviews expert opinions on combining pharmacologic treatments like minoxidil with hair transplantation, reporting improved hair density and regrowth in patients with partially functioning follicles.

This study provides the first crystal structure of the human SRD5A2 enzyme, revealing key insights into its function and inhibition which may aid future drug development.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This study found that using an oral contraceptive with bicalutamide significantly reduced hirsutism in women with PCOS compared to an oral contraceptive alone, although it increased total cholesterol and LDL levels.

This review examines hormonal influences on acne development and available hormonal therapies but reports no new clinical results.

This study found that the HPCH-based formulation P-08–016 may facilitate finasteride deposition in the dermis, potentially offering an alternative to systemic therapy by minimizing systemic absorption.